Galena Biopharma COO Mark W. Schwartz Sells 100,000 Shares (GALE)
Galena Biopharma (NASDAQ:GALE) COO Mark W. Schwartz sold 100,000 shares of Galena Biopharma stock on the open market in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $5.57, for a total transaction of $557,000.00. Following the sale, the chief operating officer now directly owns 409,665 shares in the company, valued at approximately $2,281,834. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on GALE shares. Analysts at Maxim Group raised their price target on shares of Galena Biopharma from $9.00 to $11.00 in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock. Separately, analysts at Needham & Company raised their price target on shares of Galena Biopharma to $9.00 in a research note to investors on Tuesday, January 21st. Finally, analysts at Roth Capital raised their price target on shares of Galena Biopharma from $11.00 to $12.00 in a research note to investors on Tuesday, January 14th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $7.36.
Galena Biopharma (NASDAQ:GALE) traded down 2.59% on Friday, hitting $5.27. The stock had a trading volume of 4,869,047 shares. Galena Biopharma has a 1-year low of $1.65 and a 1-year high of $7.77. The stock’s 50-day moving average is $5.29 and its 200-day moving average is $3.10. The company’s market cap is $554.6 million.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.